Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2

NCT06710158 is registered in ClinicalTrials.gov with Tianjin ConjuStar Biologics Co., Ltd. as lead sponsor.

NCT NCT06710158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2
Lead sponsor
Tianjin ConjuStar Biologics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 5, 2024
Completion date
June 30, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancers